These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 29721366)

  • 1. TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade.
    Cervera-Carrascon V; Siurala M; Santos JM; Havunen R; Tähtinen S; Karell P; Sorsa S; Kanerva A; Hemminki A
    Oncoimmunology; 2018; 7(5):e1412902. PubMed ID: 29721366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adenovirus Armed With TNFa and IL2 Added to aPD-1 Regimen Mediates Antitumor Efficacy in Tumors Refractory to aPD-1.
    Cervera-Carrascon V; Quixabeira DCA; Santos JM; Havunen R; Milenova I; Verhoeff J; Heiniö C; Zafar S; Garcia-Vallejo JJ; van Beusechem VW; de Gruijl TD; Kalervo A; Sorsa S; Kanerva A; Hemminki A
    Front Immunol; 2021; 12():706517. PubMed ID: 34367166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.
    Vijayakumar G; McCroskery S; Palese P
    J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition.
    Cervera-Carrascon V; Quixabeira DCA; Santos JM; Havunen R; Zafar S; Hemminki O; Heiniö C; Munaro E; Siurala M; Sorsa S; Mirtti T; Järvinen P; Mildh M; Nisen H; Rannikko A; Anttila M; Kanerva A; Hemminki A
    Oncoimmunology; 2020 May; 9(1):1761229. PubMed ID: 32923123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Local therapy with an engineered oncolytic adenovirus enables antitumor response in non-injected melanoma tumors in mice treated with aPD-1.
    Quixabeira DCA; Cervera-Carrascon V; Santos JM; Clubb JHA; Kudling TV; Basnet S; Heiniö C; Grönberg-Vähä-Koskela S; Anttila M; Havunen R; Kanerva A; Hemminki A
    Oncoimmunology; 2022; 11(1):2028960. PubMed ID: 35083096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adenovirus Coding for Interleukin-2 and Tumor Necrosis Factor Alpha Replaces Lymphodepleting Chemotherapy in Adoptive T Cell Therapy.
    Santos JM; Cervera-Carrascon V; Havunen R; Zafar S; Siurala M; Sorsa S; Anttila M; Kanerva A; Hemminki A
    Mol Ther; 2018 Sep; 26(9):2243-2254. PubMed ID: 30017877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adenoviral Delivery of Tumor Necrosis Factor-α and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma.
    Siurala M; Havunen R; Saha D; Lumen D; Airaksinen AJ; Tähtinen S; Cervera-Carrascon V; Bramante S; Parviainen S; Vähä-Koskela M; Kanerva A; Hemminki A
    Mol Ther; 2016 Aug; 24(8):1435-43. PubMed ID: 27357626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytokine-Coding Oncolytic Adenovirus TILT-123 Is Safe, Selective, and Effective as a Single Agent and in Combination with Immune Checkpoint Inhibitor Anti-PD-1.
    Havunen R; Kalliokoski R; Siurala M; Sorsa S; Santos JM; Cervera-Carrascon V; Anttila M; Hemminki A
    Cells; 2021 Jan; 10(2):. PubMed ID: 33513935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T-Cell Therapy Enabling Adenoviruses Coding for IL2 and TNFα Induce Systemic Immunomodulation in Mice With Spontaneous Melanoma.
    Tähtinen S; Blattner C; Vähä-Koskela M; Saha D; Siurala M; Parviainen S; Utikal J; Kanerva A; Umansky V; Hemminki A
    J Immunother; 2016; 39(9):343-354. PubMed ID: 27741089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma.
    Vijayakumar G; Palese P; Goff PH
    EBioMedicine; 2019 Nov; 49():96-105. PubMed ID: 31676387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TNFa and IL2 Encoding Oncolytic Adenovirus Activates Pathogen and Danger-Associated Immunological Signaling.
    Heiniö C; Havunen R; Santos J; de Lint K; Cervera-Carrascon V; Kanerva A; Hemminki A
    Cells; 2020 Mar; 9(4):. PubMed ID: 32225009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Favorable alteration of tumor microenvironment by immunomodulatory cytokines for efficient T-cell therapy in solid tumors.
    Tähtinen S; Kaikkonen S; Merisalo-Soikkeli M; Grönberg-Vähä-Koskela S; Kanerva A; Parviainen S; Vähä-Koskela M; Hemminki A
    PLoS One; 2015; 10(6):e0131242. PubMed ID: 26107883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncolytic Adenoviruses Armed with Tumor Necrosis Factor Alpha and Interleukin-2 Enable Successful Adoptive Cell Therapy.
    Havunen R; Siurala M; Sorsa S; Grönberg-Vähä-Koskela S; Behr M; Tähtinen S; Santos JM; Karell P; Rusanen J; Nettelbeck DM; Ehrhardt A; Kanerva A; Hemminki A
    Mol Ther Oncolytics; 2017 Mar; 4():77-86. PubMed ID: 28345026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity.
    Santos JM; Heiniö C; Cervera-Carrascon V; Quixabeira DCA; Siurala M; Havunen R; Butzow R; Zafar S; de Gruijl T; Lassus H; Kanerva A; Hemminki A
    J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31940588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses.
    Rajani K; Parrish C; Kottke T; Thompson J; Zaidi S; Ilett L; Shim KG; Diaz RM; Pandha H; Harrington K; Coffey M; Melcher A; Vile R
    Mol Ther; 2016 Feb; 24(1):166-74. PubMed ID: 26310630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intratumoral expression of IL-7 and IL-12 using an oncolytic virus increases systemic sensitivity to immune checkpoint blockade.
    Nakao S; Arai Y; Tasaki M; Yamashita M; Murakami R; Kawase T; Amino N; Nakatake M; Kurosaki H; Mori M; Takeuchi M; Nakamura T
    Sci Transl Med; 2020 Jan; 12(526):. PubMed ID: 31941828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective intravenous delivery of adenovirus armed with TNFα and IL-2 improves anti-PD-1 checkpoint blockade in non-small cell lung cancer.
    Kudling TV; Clubb JHA; Pakola S; Quixabeira DCA; Lähdeniemi IAK; Heiniö C; Arias V; Havunen R; Cervera-Carrascon V; Santos JM; Sutinen E; Räsänen J; Borenius K; Mäyränpää MI; Aaltonen E; Sorsa S; Hemminki O; Kanerva A; Verschuren EW; Ilonen I; Hemminki A
    Oncoimmunology; 2023; 12(1):2241710. PubMed ID: 37546696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncolytic adenoviruses: a game changer approach in the battle between cancer and the immune system.
    Cervera-Carrascon V; Havunen R; Hemminki A
    Expert Opin Biol Ther; 2019 May; 19(5):443-455. PubMed ID: 30905206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adenovirus Improves the Efficacy of Adoptive T-cell Therapy by Recruiting Immune Cells to and Promoting Their Activity at the Tumor.
    Tähtinen S; Grönberg-Vähä-Koskela S; Lumen D; Merisalo-Soikkeli M; Siurala M; Airaksinen AJ; Vähä-Koskela M; Hemminki A
    Cancer Immunol Res; 2015 Aug; 3(8):915-25. PubMed ID: 25977260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.